Iterum Therapeutics Plc Quick Ratio (ITRM) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Iterum Therapeutics Plc  (NASDAQ: ITRM)

Iterum Therapeutics Plc's Quick Ratio

ITRM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 1.79 below Iterum Therapeutics Plc average.

Within Major Pharmaceutical Preparations industry 287 other companies have achieved higher Quick Ratio than Iterum Therapeutics Plc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 719 to 1141.

Explain Quick Ratio?
How much Cash & cash equivalents ITRM´s has?
What are ITRM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ITRM Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change -67.12 % -68.15 % -80.31 % 30.23 % 14.07 %
Y / Y Cash & cash equivalent Change -24.13 % 11.17 % -30.54 % 0.81 % -59.6 %
Quick Ratio MRQ 1.79 2.44 3.61 1.37 0.78
ITRM's Total Ranking # 1141 # 719 # 562 # 1311 # 1640
Seq. Current Liabilities Change 15.09 % 52.48 % -80.1 % -5.87 % 11.49 %
Seq. Cash & cash equivalent Change -15.54 % 2.96 % -47.56 % 66.36 % 23.77 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 288
Healthcare Sector # 495
Overall Market # 1141


Quick Ratio Statistics
High Average Low
13.46 3.69 0.13
(Sep 30 2018)   (Dec 31 2019)




Financial Statements
Iterum Therapeutics Plc's Current Liabilities $ 6 Millions Visit ITRM's Balance sheet
Iterum Therapeutics Plc's Cash & cash equivalent $ 11 Millions Visit ITRM's Balance sheet
Source of ITRM's Sales Visit ITRM's Sales by Geography


Cumulative Iterum Therapeutics Plc's Quick Ratio

ITRM's Quick Ratio for the trailling 12 Months

ITRM Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -51.19 % -29.97 % -3.33 % 46.02 % 51.5 %
Y / Y Cash & cash equivalent TTM Growth -11.06 % -28.35 % -48.69 % -56.16 % -64.62 %
Quick Ratio TTM 1.87 1.42 1.11 0.97 1.02
Total Ranking TTM # 3234 # 2986 # 2561 # 749 # 3099
Seq. Current Liabilities TTM Growth -27.8 % -20.2 % -20.16 % 6.12 % 3.58 %
Seq. Cash & cash equivalent TTM Growth -5.44 % 2.08 % -8.11 % 0.29 % -23.83 %

Quick ratio ranking by company, industry and sector >> Back to ITRM Financial Strength Comparisons >> Go to Compare ITRM Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Iterum Therapeutics Plc's average Cash & cash equivalent, this led to increase in in Iterum Therapeutics Plc's Quick Ratio to 1.87, Quick Ratio remained below ITRM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Iterum Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2986 to 3234.

Explain Quick Ratio?
How much Cash & cash equivalents ITRM´s has?
What are ITRM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 422
Healthcare Sector # 866
Within the Market # 3234


trailing twelve months Quick Ratio Statistics
High Average Low
7.89 3.14 0.3
(Dec 31 2022)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Scynexis Inc   4.74 $ 37.928  Millions$ 8.006  Millions
Lantern Pharma Inc   4.68 $ 18.460  Millions$ 3.946  Millions
Silence Therapeutics Plc  4.67 $ 109.133  Millions$ 23.363  Millions
Ibio inc   4.65 $ 28.137  Millions$ 6.048  Millions
Minerva Neurosciences Inc   4.60 $ 12.287  Millions$ 2.672  Millions
Kura Oncology Inc   4.53 $ 549.665  Millions$ 121.304  Millions
Q32 Bio Inc   4.41 $ 49.039  Millions$ 11.110  Millions
Genelux Corporation  4.38 $ 20.915  Millions$ 4.772  Millions
Assembly Biosciences Inc   4.36 $ 232.557  Millions$ 53.380  Millions
Decoy Therapeutics Inc   4.36 $ 4.810  Millions$ 1.104  Millions
Annexon Inc   4.33 $ 188.721  Millions$ 43.580  Millions
Hutchmed china Limited  4.33 $ 1,367.275  Millions$ 315.775  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Generation Bio Co   4.26 $ 89.622  Millions$ 21.040  Millions
Skye Bioscience Inc   4.22 $ 35.312  Millions$ 8.368  Millions
Dermata Therapeutics Inc   4.20 $ 4.664  Millions$ 1.111  Millions
Lisata Therapeutics Inc   4.16 $ 18.998  Millions$ 4.568  Millions
Enveric Biosciences Inc   4.15 $ 3.758  Millions$ 0.906  Millions
Metsera Inc   4.13 $ 448.461  Millions$ 108.494  Millions
Nektar Therapeutics  4.07 $ 270.208  Millions$ 66.340  Millions
Rhythm Pharmaceuticals Inc   4.01 $ 416.052  Millions$ 103.643  Millions
Adial Pharmaceuticals Inc   3.99 $ 4.606  Millions$ 1.155  Millions
Dogwood Therapeutics inc   3.98 $ 10.127  Millions$ 2.542  Millions
Bioharvest Sciences Inc   3.98 $ 23.025  Millions$ 5.787  Millions
Syndax Pharmaceuticals Inc   3.98 $ 454.174  Millions$ 114.187  Millions
Oragenics Inc   3.97 $ 11.404  Millions$ 2.874  Millions
Maravai Lifesciences Holdings Inc   3.96 $ 243.574  Millions$ 61.574  Millions
Pyxis Oncology Inc   3.93 $ 76.256  Millions$ 19.382  Millions
Enanta Pharmaceuticals Inc  3.89 $ 188.864  Millions$ 48.555  Millions
Sol gel Technologies Ltd   3.89 $ 23.999  Millions$ 6.171  Millions

Date modified: 2026-09-26T07:34:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.